Zimmer Biomet Holdings (FRA:ZIM) Cyclically Adjusted Revenue per Share: €37.13 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ZIM Zimmer Biomet Holdings Inc FRA:ZIM
80 GF Score
Price €78.20
GF Value €105.38
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Zimmer Biomet Holdings Cyclically Adjusted Revenue per Share?

Zimmer Biomet Holdings FRA:ZIM -1.11% 80 Cyclically Adjusted Revenue per Share is €37.13 as of Mar. 2026. GuruFocus rates FRA:ZIM with a GF Score™ of 80/100 and a GF Value™ of €105.38 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zimmer Biomet Holdings's adjusted revenue per share for the three months ended in Mar. 2026 was €9.219. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €37.13 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Zimmer Biomet Holdings's average Cyclically Adjusted Revenue Growth Rate was 2.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Zimmer Biomet Holdings was 11.30% per year. The lowest was 3.00% per year. And the median was 8.10% per year.

As of today (2026-07-17), Zimmer Biomet Holdings's current stock price is €78.20. Zimmer Biomet Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €37.13. Zimmer Biomet Holdings's Cyclically Adjusted PS Ratio of today is 2.11.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zimmer Biomet Holdings was 5.08. The lowest was 1.89. And the median was 3.49.


Zimmer Biomet Holdings  (FRA:ZIM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zimmer Biomet Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=78.20/37.13
=2.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zimmer Biomet Holdings was 5.08. The lowest was 1.89. And the median was 3.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zimmer Biomet Holdings Cyclically Adjusted Revenue per Share Related Terms


Zimmer Biomet Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zimmer Biomet Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zimmer Biomet Holdings Cyclically Adjusted Revenue per Share Chart

Zimmer Biomet Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.84 36.93 36.69 40.52 36.55

Zimmer Biomet Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.87 36.80 36.59 36.55 37.13

FRA:ZIM vs STE, PEN, GMED: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Zimmer Biomet Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zimmer Biomet Holdings Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's Cyclically Adjusted PS Ratio falls into.


FRA:ZIM
80GF Score
Zimmer Biomet Holdings Inc FRA:ZIM
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zimmer Biomet Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zimmer Biomet Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=9.219/330.2130*330.2130
=9.219

Current CPI (Mar. 2026) = 330.2130.

Zimmer Biomet Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 8.632 241.018 11.826
201609 8.048 241.428 11.008
201612 9.343 241.432 12.779
201703 9.080 243.801 12.298
201706 8.518 244.955 11.483
201709 7.457 246.819 9.977
201712 8.567 246.524 11.475
201803 7.997 249.554 10.582
201806 8.399 251.989 11.006
201809 7.663 252.439 10.024
201812 8.919 251.233 11.723
201903 8.495 254.202 11.035
201906 8.535 256.143 11.003
201909 8.301 256.759 10.676
201912 9.202 256.974 11.825
202003 7.818 258.115 10.002
202006 5.265 257.797 6.744
202009 7.856 260.280 9.967
202012 4.705 260.474 5.965
202103 6.400 264.877 7.979
202106 6.946 271.696 8.442
202109 6.802 274.310 8.188
202112 7.486 278.802 8.866
202203 7.188 287.504 8.256
202206 8.015 296.311 8.932
202209 8.019 296.808 8.922
202212 8.181 296.797 9.102
202303 8.128 301.836 8.892
202306 8.221 305.109 8.897
202309 7.824 307.789 8.394
202312 8.533 306.746 9.186
202403 8.429 312.332 8.912
202406 8.741 314.175 9.187
202409 8.097 315.301 8.480
202412 9.661 315.605 10.108
202503 8.843 319.799 9.131
202506 9.082 322.561 9.297
202509 8.577 324.800 8.720
202512 9.687 324.054 9.871
202603 9.219 330.213 9.219

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €37.13 mean?
Zimmer Biomet Holdings (FRA:ZIM) has a Cyclically Adjusted Revenue per Share of €37.13 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zimmer Biomet Holdings and its competitors.
Is Zimmer Biomet Holdings' Cyclically Adjusted Revenue per Share too high?
Zimmer Biomet Holdings' current Cyclically Adjusted Revenue per Share is €37.13. Overall, Zimmer Biomet Holdings has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Cyclically Adjusted Revenue per Share compare to STE and PEN?
Zimmer Biomet Holdings' Cyclically Adjusted Revenue per Share of €37.13 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zimmer Biomet Holdings and its competitors. Zimmer Biomet Holdings's current Cyclically Adjusted Revenue per Share is €37.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (FRA:ZIM) is currently considered Modestly Undervalued. The stock's GF Value™ is €105.38, compared to a current price of €78.20 — trading 25.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €37.13. Zimmer Biomet Holdings' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zimmer Biomet Holdings (FRA:ZIM), the current Cyclically Adjusted Revenue per Share is €37.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zimmer Biomet Holdings (FRA:ZIM) Overvalued in 2026?

Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued. The current stock price of €78.20 is trading 25.8% below its estimated GF Value™ of €105.38. GuruFocus considers Zimmer Biomet Holdings to be Modestly Undervalued.

Key valuation signals for FRA:ZIM:

  • Cyclically Adjusted Revenue per Share: €37.13
  • GF Value™: €105.38 vs. price of €78.20 (25.8% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the FRA:ZIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zimmer Biomet Holdings Business Description

Address 345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
80GF Score

Get the complete analysis for FRA:ZIM

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.20
Price
€105.38
GF Value